Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method

• Published in: Scientific reports Vol. 9; no. 1; pp. 13783 - 9
• Main Authors: Winnicki, Wolfgang, Sunder-Plassmann, Gere, Sengölge, Gürkan, Handisurya, Ammon, Herkner, Harald, Kornauth, Christoph, Bielesz, Bernhard, Wagner, Ludwig, Kikić, Željko, Pajenda, Sahra, Reiter, Thomas, Schairer, Benjamin, Schmidt, Alice
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.09.2019; Nature Publishing Group
• Subjects: 692/4022/1585/2759; 692/4022/1585/2759/1523; 82; 82/1; Adult; Biomarkers; Biomarkers - blood; Cross-Sectional Studies; Diagnosis; End-stage renal disease; Enzyme-linked immunosorbent assay; Female; Glomerular filtration rate; Glomerular Filtration Rate - physiology; Glomerulonephritis; Glomerulonephritis - blood; Glomerulosclerosis, Focal Segmental - blood; Glomerulosclerosis, Focal Segmental - diagnosis; Glomerulosclerosis, Focal Segmental - pathology; Humanities and Social Sciences; Humans; Kidney diseases; Kidney Failure, Chronic - blood; Kidney transplantation; Kidney Transplantation - mortality; Male; Middle Aged; multidisciplinary; Prognosis; Receptors, Urokinase Plasminogen Activator - blood; Recurrence; Retrospective Studies; Science; Science (multidisciplinary); Thrombolytic drugs; U-Plasminogen activator
• DOI: 10.1038/s41598-019-50405-8
• ISSN: 2045-2322

The plasma soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker for focal segmental glomerulosclerosis (FSGS), but its value is under discussion because of ambiguous results arising from different ELISA methods in previous studies. The aim of this study was to compare diagnostic performance of two leading suPAR ELISA kits and examine four objectives in 146 subjects: (1) plasma suPAR levels according to glomerular disease (primary, secondary and recurrent FSGS after kidney transplantation, other glomerulonephritis) and in healthy controls; (2) suPAR levels based on glomerular filtration rate; (3) sensitivity and specificity of suPAR for FSGS diagnosis and determination of optimal cut-offs; (4) suPAR as prognostic tool. Patients with FSGS showed significant higher suPAR values than patients with other glomerulonephritis and healthy individuals. This applied to subjects with and without chronic kidney disease. Although both suPARnostic™ assay and Quantikine Human uPAR ELISA Kit exerted high sensitivity and specificity for FSGS diagnosis, their cut-off values of 4.644 ng/mL and 2.789 ng/mL were significantly different. Higher suPAR was furthermore predictive for progression to end-stage renal disease. In summary, suPAR values must be interpreted in the context of population and test methods used. Knowing test specific cut-offs makes suPAR a valuable biomarker for FSGS.